Market Place
Sourcing Support
AGC Bio embarks on turnaround strategy under new CEO
11 Nov 2024 //
FIERCE PHARMA
AGC Biologics Appoints Alberto Santagostino as CEO
28 Oct 2024 //
ACCESSWIRE
AGC Biologics Achieves Approval for 2024 BLA
17 Oct 2024 //
ACCESSWIRE
AGC Biologics Begins New Copenhagen Manufacturing Building
10 Oct 2024 //
ACCESSWIRE
AGC Biologics Strengthens Portfolio With Latest FDA Approval
30 Sep 2024 //
ACCESSWIRE
AGC Bio lays off staffers, sidelines Colorado plant
24 Sep 2024 //
FIERCE PHARMA
AGC and Medinet sign agreement for cell therapy CDMO business
12 Sep 2024 //
INDIANPHARMAPOST
AGC Biologics Gains FDA Approval For Copenhagen Facility
28 Aug 2024 //
ACCESSWIRE
NEC Bio And AGC Biologics To Manufacture Cancer Vaccines
08 Aug 2024 //
ACCESSWIRE
Essential Pharma Signs Strategic Agreement with AGC Biologics
11 Jun 2024 //
CONTRACT PHARMA
AGC Biologics: Doubles Copenhagen Bioreactor Capacity After Expansion
04 Jun 2024 //
ACCESSWIRE
AGC, BioConnection Partner On End-To-End Biopharma Offering
22 May 2024 //
GLOBENEWSWIRE
AGC Biologics, BioConnection forge partnership to be an alternative to WuXi
22 May 2024 //
ENDPTS
AGC plots around 100 layoffs amid tough business environment
10 May 2024 //
FIERCE PHARMA
FDA Issues Form 483 to AGC Biologics
31 Jan 2024 //
FDA
AGC Biologics to build new government-funded $350M Japanese facility
04 Jan 2024 //
ENDPTS
AGC Biologics Milan Receives Special Award Mention by Confindustria
01 Nov 2023 //
BUSINESSWIRE
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s Product
25 Oct 2023 //
BUSINESSWIRE
AGC Biologics Inks TCR-T Cell Services Agreement with Medigene
25 Oct 2023 //
CONTRACT PHARMA
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
12 Oct 2023 //
BUSINESSWIRE
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material
14 Sep 2023 //
BUSINESSWIRE
AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus
23 Aug 2023 //
BUSINESSWIRE
AGC beefs up Colorado cell and gene therapy production facility
23 Aug 2023 //
FIERCE PHARMA
AGC Biologics Partners with Asahi Kasei Pharma on Clinical Antibody Project
15 Aug 2023 //
BUSINESSWIRE
AGC finishes expansion of gene therapy facility in Italy
09 Aug 2023 //
FIERCE PHARMA
AGC Biologics Introduces AGCellerate
05 Jun 2023 //
BUSINESSWIRE
AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms
16 May 2023 //
BUSINESSWIRE
AGC Biologics Received Bioprocessing Excellence Award in Japan
25 Apr 2023 //
BUSINESSWIRE
AGC Biologics Signs Exosome Agreement with The Jikei University in Japan
03 Apr 2023 //
BUSINESSWIRE
AGC Biologics Copenhagen named Børsen Gazelle company for 2022
09 Feb 2023 //
PRESS RELEASE
Genenta and AGC Biologics Enter Development and Manufacturing Service Agreement
07 Feb 2023 //
GLOBENEWSWIRE
AGC Supports Production of Provention Bio’s Type 1 Diabetes Therapy, TZIELD
24 Jan 2023 //
BUSINESSWIRE
AGC Biologics, Gore Partner on Purification & Mfg. Services for Antibodies
13 Dec 2022 //
CONTRACTPHARMA
AGC Biologics Honored for Innovations in Cell Line Development
13 Oct 2022 //
PRESS RELEASE
AGC Biologics and Evax Partner to Advance Equine Allergy Vaccine Candidate
09 Sep 2022 //
GLOBENEWSWIRE
AGC and RoosterBio partner for cell and exosome therapy manufacturing
17 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
28 Jul 2022 //
CONTRACTPHARMA
AGC Biologics Named Manufacturing Company of the Year by American
29 Jun 2022 //
PRESS RELEASE
AGC Biologics Expands Cell and Gene Therapy CDMO Capacity at its U.S. site
18 May 2022 //
AGC
AGC Biologics Provides Aid to Ukraine
11 May 2022 //
PRESS RELEASE
AGC to Expand Synthetic Pharmaceutical Production Base in Spain
07 Apr 2022 //
PRNEWSWIRE
AGC to use recently-expanded Germany site for peanut allergy drug trials
01 Apr 2022 //
ENDPTS
Allergy Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
31 Mar 2022 //
PRESS RELEASE
AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA
08 Feb 2022 //
PRESS RELEASE
AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Facility
18 Jan 2022 //
PRESS RELEASE
AGC Biologics Appoints Jean-Baptiste Agnus as CBO
04 Nov 2021 //
CONTRACTPHARMA
AGC unveils German expansion plans
16 Sep 2021 //
ENDPTS
AGC Biologics expands pDNA and mRNA manufacturing capacity
13 Sep 2021 //
BIOSPECTRUM ASIA
AGC Biologics Breaks Ground on New Facility
23 Aug 2021 //
CONTRACT PHARMA
Often-passed plant in Colorado has a new owner, who`s already operating nearby
07 Jul 2021 //
ENDPTS
AGC is picking up a second commercial plant in CO
03 Jul 2021 //
FIERCEPHARMA
AGC Biologics to Acquire Novartis Facility in Longmont, CO
02 Jul 2021 //
CONTRACTPHARMA
AGC is picking up a second commercial plant in CO
02 Jul 2021 //
FIERCEPHARMA
Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III
24 Jun 2021 //
CONTRACTPHARMA
AGC Biologics Inks Supply Deal for COVID-19 Vaccine
10 Jun 2021 //
CONTRACT PHARMA
AGC adds major Covid-19 vaccine maker to the client list with BioNTech pact
10 Jun 2021 //
ENDPTS
AGC Biologics and Oculis Enter Manufacturing Deal
07 May 2021 //
CONTRACTPHARMA
Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02
06 May 2021 //
GLOBENEWSWIRE
AGC Biologics Expands Partnership with Rocket Pharmaceuticals
21 Apr 2021 //
CONTRACTPHARMA
